指南与共识生殖医学

未来不孕症研究的十大优先领域:国际共识开发研究

Top 10 priorities for future infertility research: an international consensus development study† ‡.
指南 / 共识 · Hum Reprod · 2020-01-01

该国际共识研究通过调查、系统综述和共识会议,确定了男性不孕、女性及不明原因不孕、医学辅助生殖以及伦理、可及性与照护组织四个领域的十大研究优先领域。共识会议有来自11个国家的41名参与者,优先领域强调预防、治疗、长期影响及心理支持、可及性和监管。

要点

  • 确定了男性不孕、女性及不明原因不孕、医学辅助生殖、伦理与照护组织四大领域的十大研究优先领域。
  • 优先领域涵盖预防、治疗、长期影响及心理支持、可及性和监管等被忽视的方向。
  • 解决这些优先领域需多种研究方法,包括实验室科学、定性和定量研究及群体科学。

核心结论

  • 通过正式共识方法确定了不孕症四个领域的十大研究优先领域,强调预防、治疗、长期影响及心理支持、可及性和监管等被忽视的方向。

研究设计与样本

  • 国际共识开发研究,采用James Lind Alliance倡导的正式共识方法和改良名义群体技术。
  • 初始调查由来自40个国家的388名参与者完成,提交423个潜在研究问题。
  • 231个确认的研究不确定性进入中期优先排序调查,由来自43个国家的317名受访者完成。
  • 共识开发会议有来自11个国家的41名参与者,确定四个类别各自的十大研究优先领域。

主要发现

  • 四个类别(男性不孕、女性及不明原因不孕、医学辅助生殖、伦理与照护组织)各确定十大研究优先领域。
  • 优先领域多样,涉及预防、治疗和不孕症长期影响的问题。
  • 优先领域强调解决不孕症的情感和心理影响、改善治疗可及性(尤其低资源环境)及确保适当监管。

关键数值与推荐

  • 初始调查:388名参与者来自40个国家,提交423个潜在研究问题。
  • 中期优先排序调查:231个确认的研究不确定性,317名受访者来自43个国家。
  • 共识开发会议:41名参与者来自11个国家。

临床怎么用

  • 研究资助组织和研究者可参考这些优先领域制定未来研究议程。
  • 临床医生可关注优先领域中的心理支持、治疗可及性和监管问题,以改善照护。

局限性

  • 共识开发方法固有局限,包括参与者样本代表性、基于专业判断的方法学决策和任意共识定义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Can the priorities for future research in infertility be identified? SUMMARY ANSWER: The top 10 research priorities for the four areas of male infertility, female and unexplained infertility, medically assisted reproduction and ethics, access and organization of care for people with fertility problems were identified. WHAT IS KNOWN ALREADY: Many fundamental questions regarding the prevention, management and consequences of infertility remain unanswered. This is a barrier to improving the care received by those people with fertility problems. STUDY DESIGN, SIZE, DURATION: Potential research questions were collated from an initial international survey, a systematic review of clinical practice guidelines and Cochrane systematic reviews. A rationalized list of confirmed research uncertainties was prioritized in an interim international survey. Prioritized research uncertainties were discussed during a consensus development meeting. Using a formal consensus development method, the modified nominal group technique, diverse stakeholders identified the top 10 research priorities for each of the categories male infertility, female and unexplained infertility, medically assisted reproduction and ethics, access and organization of care. PARTICIPANTS/MATERIALS, SETTING, METHODS: Healthcare professionals, people with fertility problems and others (healthcare funders, healthcare providers, healthcare regulators, research funding bodies and researchers) were brought together in an open and transparent process using formal consensus methods advocated by the James Lind Alliance. MAIN RESULTS AND THE ROLE OF CHANCE: The initial survey was completed by 388 participants from 40 countries, and 423 potential research questions were submitted. Fourteen clinical practice guidelines and 162 Cochrane systematic reviews identified a further 236 potential research questions. A rationalized list of 231 confirmed research uncertainties was entered into an interim prioritization survey completed by 317 respondents from 43 countries. The top 10 research priorities for each of the four categories male infertility, female and unexplained infertility (including age-related infertility, ovarian cysts, uterine cavity abnormalities and tubal factor infertility), medically assisted reproduction (including ovarian stimulation, IUI and IVF) and ethics, access and organization of care were identified during a consensus development meeting involving 41 participants from 11 countries. These research priorities were diverse and seek answers to questions regarding prevention, treatment and the longer-term impact of infertility. They highlight the importance of pursuing research which has often been overlooked, including addressing the emotional and psychological impact of infertility, improving access to fertility treatment, particularly in lower resource settings and securing appropriate regulation. Addressing these priorities will require diverse research methodologies, including laboratory-based science, qualitative and quantitative research and population science. LIMITATIONS, REASONS FOR CAUTION: We used consensus development methods, which have inherent limitations, including the representativeness of the participant sample, methodological decisions informed by professional judgment and arbitrary consensus definitions. WIDER IMPLICATIONS OF THE FINDINGS: We anticipate that identified research priorities, developed to specifically highlight the most pressing clinical needs as perceived by healthcare professionals, people with fertility problems and others, will help research funding organizations and researchers to develop their future research agenda. STUDY FUNDING/COMPETING INTEREST(S): The study was funded by the Auckland Medical Research Foundation, Catalyst Fund, Royal Society of New Zealand and Maurice and Phyllis Paykel Trust. G.D.A. reports research sponsorship from Abbott, personal fees from Abbott and LabCorp, a financial interest in Advanced Reproductive Care, committee membership of the FIGO Committee on Reproductive Medicine, International Committee for Monitoring Assisted Reproductive Technologies, International Federation of Fertility Societies and World Endometriosis Research Foundation, and research sponsorship of the International Committee for Monitoring Assisted Reproductive Technologies from Abbott and Ferring. Siladitya Bhattacharya reports being the Editor-in-Chief of Human Reproduction Open and editor for the Cochrane Gynaecology and Fertility Group. J.L.H.E. reports being the Editor Emeritus of Human Reproduction. A.W.H. reports research sponsorship from the Chief Scientist's Office, Ferring, Medical Research Council, National Institute for Health Research and Wellbeing of Women and consultancy fees from AbbVie, Ferring, Nordic Pharma and Roche Diagnostics. M.L.H. reports grants from Merck, grants from Myovant, grants from Bayer, outside the submitted work and ownership in Embrace Fertility, a private fertility company. N.P.J. reports research sponsorship from AbbVie and Myovant Sciences and consultancy fees from Guerbet, Myovant Sciences, Roche Diagnostics and Vifor Pharma. J.M.L.K. reports research sponsorship from Ferring and Theramex. R.S.L. reports consultancy fees from AbbVie, Bayer, Ferring, Fractyl, Insud Pharma and Kindex and research sponsorship from Guerbet and Hass Avocado Board. B.W.M. reports consultancy fees from Guerbet, iGenomix, Merck, Merck KGaA and ObsEva. E.H.Y.N. reports research sponsorship from Merck. C.N. reports being the Co Editor-in-Chief of Fertility and Sterility and Section Editor of the Journal of Urology, research sponsorship from Ferring and retains a financial interest in NexHand. J.S. reports being employed by a National Health Service fertility clinic, consultancy fees from Merck for educational events, sponsorship to attend a fertility conference from Ferring and being a clinical subeditor of Human Fertility. A.S. reports consultancy fees from Guerbet. J.W. reports being a statistical editor for the Cochrane Gynaecology and Fertility Group. A.V. reports that he is a Statistical Editor of the Cochrane Gynaecology & Fertility Review Group and the journal Reproduction. His employing institution has received payment from Human Fertilisation and Embryology Authority for his advice on review of research evidence to inform their 'traffic light' system for infertility treatment 'add-ons'. N.L.V. reports consultancy and conference fees from Ferring, Merck and Merck Sharp and Dohme. The remaining authors declare no competing interests in relation to the present work. All authors have completed the disclosure form. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Duffy JMN, Adamson GD, Benson E, et al. Top 10 priorities for future infertility research: an international consensus development study† ‡. Hum Reprod. 2020. PMID: 33252677. doi:10.1093/humrep/deaa242

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。